Registration Newsletter News Contact Home About us The company History Management Board Scientific founders Scientific advice Science and platform About epilepsy About NPY About gene therapy About AAV vectors CombiGene's platform Project The epilepsy project Other projects Investor Relations Company and share information Insiders and transactions Largest owner News Annual reports and prospectuses Videos and interviews English Select a page Development of new treatment methods for neurological diseases, with higher accuracy, better effect and fewer side effects Genevägen # 3 2017, News from CombiGene September 26, 2017 Our idea with "Genevägen" is to keep you updated about the company's journey and development and let you take part in our research findings and successes along the way. Number 3 >> Number 2 >> Number 1 >> See all news >> CombiGene AB Medicon Village SE-223 81 Lund Visiting address: Scheelevägen 2 Morten Albrechtsen , born 1964, has extensive experience in CNS drug development including drugs against Alzheimer's (Enkam), depression (Boehringer Ingelheim), addiction (Nycomed, Saniona), pain control (Nycomed), insomnia (Blake Insomnia Inc. / Zleepax), and stroke (Boehringer Ingelheim, Enkam). His experience spans from pre-clinical and clinical development to regulatory approval and to post-approval commercialization, and comprises both biological products and small molecules.